182 related articles for article (PubMed ID: 20732407)
1. In house validation of recombinant yeast estrogen and androgen receptor agonist and antagonist screening assays.
Kolle SN; Kamp HG; Huener HA; Knickel J; Verlohner A; Woitkowiak C; Landsiedel R; van Ravenzwaay B
Toxicol In Vitro; 2010 Oct; 24(7):2030-40. PubMed ID: 20732407
[TBL] [Abstract][Full Text] [Related]
2. Screening chemicals for thyroid-disrupting activity: A critical comparison of mammalian and amphibian models.
Pickford DB
Crit Rev Toxicol; 2010 Nov; 40(10):845-92. PubMed ID: 20684730
[TBL] [Abstract][Full Text] [Related]
3. Screening for (anti)androgenic properties using a standard operation protocol based on the human stably transfected androgen sensitive PALM cell line. First steps towards validation.
Freyberger A; Witters H; Weimer M; Lofink W; Berckmans P; Ahr HJ
Reprod Toxicol; 2010 Aug; 30(1):9-17. PubMed ID: 19836445
[TBL] [Abstract][Full Text] [Related]
4. Multiple hormonal activities of UV filters and comparison of in vivo and in vitro estrogenic activity of ethyl-4-aminobenzoate in fish.
Kunz PY; Fent K
Aquat Toxicol; 2006 Oct; 79(4):305-24. PubMed ID: 16911836
[TBL] [Abstract][Full Text] [Related]
5. An ongoing validation of a Tier I screening battery for detecting endocrine-active compounds (EACs).
O'Connor JC; Cook JC; Slone TW; Makovec GT; Frame SR; Davis LG
Toxicol Sci; 1998 Nov; 46(1):45-60. PubMed ID: 9928668
[TBL] [Abstract][Full Text] [Related]
6. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
[TBL] [Abstract][Full Text] [Related]
7. Estrogenic and androgenic activities of TBBA and TBMEPH, metabolites of novel brominated flame retardants, and selected bisphenols, using the XenoScreen XL YES/YAS assay.
Fic A; Žegura B; Gramec D; Mašič LP
Chemosphere; 2014 Oct; 112():362-9. PubMed ID: 25048928
[TBL] [Abstract][Full Text] [Related]
8. A testing strategy for the identification of mammalian, systemic endocrine disruptors with particular focus on steroids.
Kolle SN; Ramirez T; Kamp HG; Buesen R; Flick B; Strauss V; van Ravenzwaay B
Regul Toxicol Pharmacol; 2012 Jul; 63(2):259-78. PubMed ID: 22554500
[TBL] [Abstract][Full Text] [Related]
9. Endocrine toxicology--contributions of in vitro methods to the 3R concept.
Freyberger A; Scholz G
ALTEX; 2004; 21 Suppl 3():20-7. PubMed ID: 15057405
[TBL] [Abstract][Full Text] [Related]
10. A yeast assay based on the gilthead sea bream (teleost fish) estrogen receptor beta for monitoring estrogen mimics.
Passos AL; Pinto PI; Power DM; Canario AV
Ecotoxicol Environ Saf; 2009 Jul; 72(5):1529-37. PubMed ID: 19303142
[TBL] [Abstract][Full Text] [Related]
11. Alternatives to in vivo tests to detect endocrine disrupting chemicals (EDCs) in fish and amphibians--screening for estrogen, androgen and thyroid hormone disruption.
Scholz S; Renner P; Belanger SE; Busquet F; Davi R; Demeneix BA; Denny JS; Léonard M; McMaster ME; Villeneuve DL; Embry MR
Crit Rev Toxicol; 2013 Jan; 43(1):45-72. PubMed ID: 23190036
[TBL] [Abstract][Full Text] [Related]
12. Widely used pharmaceuticals present in the environment revealed as in vitro antagonists for human estrogen and androgen receptors.
Ezechiáš M; Janochová J; Filipová A; Křesinová Z; Cajthaml T
Chemosphere; 2016 Jun; 152():284-91. PubMed ID: 26978704
[TBL] [Abstract][Full Text] [Related]
13. Analysis of environmental endocrine disrupting activities using recombinant yeast assay in wastewater treatment plant effluents.
Li J; Wang Z; Ma M; Peng X
Bull Environ Contam Toxicol; 2010 May; 84(5):529-35. PubMed ID: 20407748
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of EPA's Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results.
Borgert CJ; Mihaich EM; Quill TF; Marty MS; Levine SL; Becker RA
Regul Toxicol Pharmacol; 2011 Apr; 59(3):397-411. PubMed ID: 21251942
[TBL] [Abstract][Full Text] [Related]
15. The application of reporter gene assays for the detection of endocrine disruptors in sport supplements.
Plotan M; Elliott CT; Scippo ML; Muller M; Antignac JP; Malone E; Bovee TF; Mitchell S; Connolly L
Anal Chim Acta; 2011 Aug; 700(1-2):34-40. PubMed ID: 21742114
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo and in vitro testis and ovary explants: utility for identifying steroid biosynthesis inhibitors and comparison to a Tier I screening battery.
Powlin SS; Cook JC; Novak S; O'Connor JC
Toxicol Sci; 1998 Nov; 46(1):61-74. PubMed ID: 9928669
[TBL] [Abstract][Full Text] [Related]
17. Hypothesis-driven weight of evidence framework for evaluating data within the US EPA's Endocrine Disruptor Screening Program.
Borgert CJ; Mihaich EM; Ortego LS; Bentley KS; Holmes CM; Levine SL; Becker RA
Regul Toxicol Pharmacol; 2011 Nov; 61(2):185-91. PubMed ID: 21803110
[TBL] [Abstract][Full Text] [Related]
18. A comparison of recombinant receptor-reporter gene bioassays and a total estrogen enzyme linked immunosorbent assay for the rapid screening of estrogenic activity in natural and waste waters.
Allinson M; Shiraishi F; Allinson G
Bull Environ Contam Toxicol; 2011 May; 86(5):461-4. PubMed ID: 21442212
[TBL] [Abstract][Full Text] [Related]
19. Vitellogenin synthesis in primary cultures of fish liver cells as endpoint for in vitro screening of the (anti)estrogenic activity of chemical substances.
Navas JM; Segner H
Aquat Toxicol; 2006 Oct; 80(1):1-22. PubMed ID: 16950525
[TBL] [Abstract][Full Text] [Related]
20. Hormonal activities of new brominated flame retardants.
Ezechiáš M; Svobodová K; Cajthaml T
Chemosphere; 2012 May; 87(7):820-4. PubMed ID: 22236593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
